EGFR and hepatocellular carcinoma: In the present study, NGI-1, similar to DDOST knockdown, inhibited the downstream signaling pathways of EGFR by decreasing its N-glycosylation, thus enhancing the sensitivity of HCC cells to lenvatinib.